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Aberrant protein glycosylation is associated with a range of pathological conditions including cancer and
possesses diagnostic importance. Translation of glycoprotein biomarkers will be facilitated by the
development of a rapid and sensitive analytical platform that simultaneously interrogates both the glycan
and protein epitopes of glycoproteins in body ﬂuids such as serum or saliva. To this end, we developed
an electrochemical biosensor based on the immobilization of a lectin on the gold electrode surface to
recognize/capture a target glycan epitope conjugated to glycoproteins, followed by detection of the
protein epitope using a target protein-speciﬁc antibody. Electrochemical signals are generated by label-
free voltammetric or impedimetric interrogation of a ferro/ferricyanide redox couple (e.g. [Fe(CN)6]
3/4)
on the sensing surface, where the change in voltammetric current or interfacial electron transfer
resistance was measured. The detection system was demonstrated using the model glycoprotein
chicken ovalbumin with Sambucus nigra agglutinin type I (SNA lectin), and exhibits femtomolar sensitivity
in the background of diluted human serum. The results obtained in this proof-of-concept study
demonstrate the possibility of using electrochemical detection for developing cheap point-of-care
diagnostics with high speciﬁcity and sensitivity for blood glycoprotein biomarkers.Introduction
Diﬀerential protein glycosylation is a feature of diverse patho-
logical conditions such as atherosclerosis, ulcerative colitis,
rheumatoid arthritis, microbial infection, Alzheimer's disease
and cancer.1 Monitoring specic glycosylation changes for
glycoprotein biomarker candidates such as fucosylated hapto-
globin (pancreatic cancer) and sialylated prostate-specic
antigen (prostate cancer) provides higher diagnostic power
compared to changes in total glycoprotein levels.2 In fact,
measurement of fucosylated a-fetoprotein in blood (AFP-L3 test)
has been approved by the FDA for early detection of hepato-
cellular carcinoma.3,4 Over the past few years, various glyco-
protein enrichment platforms have been coupled with mass
spectrometric and nuclear magnetic resonance spectroscopic
techniques to uncover disease specic glycosylation changes for
candidate glycoprotein biomarkers. These include single, serial
and multi-lectin aﬃnity chromatography,5,6 lectin magnetic
bead array (LeMBA),7,8 boronic acid9 and hydrazide chemistry10
based extraction methods. While all these methods have
excellent analytical performance in detecting candidate cancer
glyco-biomarkers, they are poorly suited for routine clinical use
due to high maintenance/running cost, requirement ofInstitute, The University of Queensland,
, Australia. E-mail: m.shiddiky@uq.edu.
3; Tel: +61-7-33464178
Nanotechnology (AIBN), Corner College
of Queensland, QLD 4072, Australiatechnical expertise, long assay time and complicated data
analysis procedures. The development of detection methods
that are user-friendly, robust, sensitive, quick and cheaper than
currently available methods is warranted to fulll important
needs for developing future diagnostics.
Electrochemical (EC) detection methods oﬀer elegant ways
for interfacing bio-recognition and transduction events and
represent substantial drivers to achieve rapid, cost-eﬀective,
sensitive, selective and accurate quantication of biomole-
cules.11–15 Among many EC methods, faradaic electrochemical
impedance spectroscopy (F-EIS) is one of the most eﬀective
methods for the label-free detection of biomolecules and for
probing the build-up of the biomaterial sensing lm on the
electrodes.16–18 In F-EIS, the binding of a target protein with its
ligand (i.e., a specic antibody) on the electrode surface can be
detected, where the change in impedance of the electrode
surface and its interface to the electrolyte solution containing a
redox probe (e.g. [Fe(CN)6]
3/4) is measured in the form of its
electron transfer resistance (Rct).19–21 This interfacial electron
transfer reaction of the redox process can also bemeasured via a
voltammetric technique, where the presence or absence of the
target proteins will alter the voltammetric current of the redox
process at the sensing surface. More recently, the diﬀerential
pulse voltammetric (DPV) interrogation of the interfacial elec-
tron transfer reaction of the [Fe(CN)6]
3/4 process generated
upon protein binding has been used as an eﬀective label-free
tool for protein detection.22,23This journal is © The Royal Society of Chemistry 2014
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View Article OnlineIn the past few years, much attention has been focused on
development of label-free electrochemical biosensors to
monitor glycosylation changes (e.g. mannosylation, gal-
actosylation, sialylation and fucosylation) in complex biological
uids24–27 using naturally occurring lectin as a glycan recogni-
tion element. These biosensors detect overall changes in the
glycan prole without monitoring a specic glycoprotein to
which glycan is attached. To increase the specicity and diag-
nostic value, analytical methods are required to detect not only
the overall status of glycosylation in the sample but also aber-
rant glycosylation for a specic glycoprotein. To overcome this
limitation, we investigated label-free electrochemical detection
methods for the simultaneous interrogation of specic glycan
on a target glycoprotein.
Here we describe the development of a simple method that
can eﬃciently and reproducibly detect both glycan and protein
epitopes of a glycoprotein in the background of a diluted serum
sample at a femtomolar concentration. This method consists of
a gold macrodisk electrode that is biochemically functionalized
with Sambucus nigra agglutinin type I lectin (SNA lectin)
[specic to recognize terminal sialic acid attached to galactose
through a-(2-6) linkage].28 The attachment of the target glyco-
protein chicken egg albumin (ovalbumin) on the SNA lectin
functionalized electrode and complexation with a polyclonal
anti-ovalbumin antibody (Fig. 1 scheme) were followed by the
F-EIS and DPV measurements. Each bimolecular layer on the
sensor surface acts as a barrier for the interfacial electron
transfer reaction of the [Fe(CN)6]
3/4 process, resulting in an
increase in Rct or a decrease in DPV current response. The
presence of target glycoprotein ovalbumin and subsequent
complexation with the polyclonal anti-ovalbumin antibody
appear to further block the [Fe(CN)6]
3/4 process from
accessing the electrode surface eﬀectively. When we monitored
Rct or DPV current responses generated from the [Fe(CN)6]
3/4
process before and aer ovalbumin capture, there was a clear
correlation between the presence of the target ovalbumin andFig. 1 (A) Schematic illustration of the preparation of an SNA lectin
immunosensing layer. (B) Schematic view of glycoprotein ovalbumin
capture and label-free detection using an anti-ovalbumin antibody
which results in increased charge transfer resistance (Rct) and a cor-
responding decrease in DPV peak current.
This journal is © The Royal Society of Chemistry 2014changes in Rct or DPV current response. To mimic clinical
scenario, we spiked ovalbumin into serum and showed linear
changes in current readout with a concentration range from 10
pg mL1 to 500 pg mL1. To the best of our knowledge, this is
the rst electrochemical method that simultaneously interro-
gates specic glycans and the target protein on which the glycan
is attached. Moreover, we believe that the simplicity of this
technology could facilitate the translation of the current glyco-
protein biomarker research.
Materials and methods
Materials
Biotin labeled Sambucus nigra agglutinin type I (SNA-I) lectin
was purchased from Vector Laboratories (USA). Lyophilized
chicken egg albumin (ovalbumin) (#A5503), polyclonal anti-
chicken egg albumin antibody produced in rabbit (#C6534),
potassium ferrocyanide, potassium ferricyanide, and KCl were
purchased from Sigma (Australia). Biotinylated BSA was
purchased from Thermo Scientic (USA) while multivalent
streptavidin was purchased from Invitrogen (USA). Human
blood sample was collected from a healthy volunteer with
consent and ethics approved by the University of Queensland
Human Ethics Committee.
Cleaning gold disk electrodes
Gold disk working electrodes (diameter ¼ 3 mm) were
purchased from CH Instruments (Austin, USA). The electrodes
were reused aer cleaning and regeneration. The electrodes
were cleaned using piranha (H2SO4 : H2O2 ¼ 3 : 1) on a soni-
cator water-bath for 30 s to 1 min (note: piranha is a highly toxic
and hazardous chemical. It has to be handled in a fume-hood
with adequate personal protective equipment. Universal safety
guidelines should be followed for its disposal). The electrodes
were then physically polished with 1 micron alumina and
subsequently with a 0.05 micron alumina slurry. Prior to elec-
trochemical cleaning, electrodes were sonicated in acetone for
20 min. Electrochemical cleaning was performed in 0.5 M
H2SO4 until reproducible characteristic gold electrode proles
were achieved.
Construction of biosensor
Immediately before functionalization, thoroughly cleaned gold
disk electrodes were dried under a ow of nitrogen gas. The
electrodes were incubated with 500 mg mL1 biotin-BSA in 1
PBS (137mMNaCl, 2 mMKCl, 10mMphosphate buﬀer, pH 7.4)
on a thermo shaker set at 25 C, 300 rpm for 45 min. The
electrodes were washed with 1 PBS aer each incubation step
3 times. The electrodes were then incubated with multivalent
streptavidin (500 mg mL1 in 1 PBS, at 25 C, 300 rpm for 45
min), followed by biotinylated SNA lectin (500 mg mL1 in 150
mMNaCl containing 0.1 mMCa2+, at 25 C, 300 rpm for 45 min)
to form the bio-recognition layer of lectin on the electrode
surface. Ovalbumin stock solution was made at a concentration
of 2 mg mL1 and stored at 30 C in aliquots. The designated
concentration of ovalbumin was freshly made (in 150 mM NaClAnalyst, 2014, 139, 5970–5976 | 5971
Fig. 2 Optimization of biosensor construction. Nyquist plots of a gold
electrode modiﬁed with (A) biotin-BSA, (C) biotin-BSA/streptavidin,
and (E) biotin-BSA/streptavidin/SNA lectin in 1 PBS buﬀer containing
2.5 mM K3[Fe(CN)6], 2.5 mM K4[Fe(CN)6]$3H2O and 0.1 M KCl. (B, D,
and F) Corresponding DPV responses obtained at a gold electrode
modiﬁed with (B) biotin-BSA, (D) biotin-BSA/streptavidin, and (F)
biotin-BSA/streptavidin/SNA lectin, respectively. Concentrations of
biotin-BSA in Fig. A & B, multivalent streptavidin in Fig. C & D (following
incubation with 500 mgmL1 of biotin-BSA), and SNA lectin in Fig. E & F
(following incubation with 500 mg mL1 biotin-BSA and 500 mg mL1
streptavidin each) were (i) 100 mg mL1, (ii) 500 mg mL1, and (iii)
1000 mg mL1.
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View Article Onlinesolution containing 0.1 mM Ca2+) prior to use and protein
capture was performed for 45 min by gentle agitation using an
intelli-mixer (PCOD Scientic). 1 in 1000 dilution of the poly-
clonal anti-ovalbumin antibody in 1 PBS for 15 min was used
for detection of captured chicken egg albumin. Designated
concentrations of ovalbumin were spiked in diluted serum (1 in
1000 dilution of serum in 150 mM NaCl solution containing
0.1 mM Ca2+).
Aer modication of the sensor surfaces (up to SNA lectin
attachment), the actual detection steps include capturing the
ovalbumin antigen followed by anti-ovalbumin detection. Both
these steps are directly followed by the label-free impedance (or
DPV) technique. Thus once the electrode is modied with the
SNA lectin, the overall detection process takes approximately 2 h.
Electrochemical measurement
All electrochemical experiments were conducted at room
temperature (25  1 C) in a standard three-electrode electro-
chemical cell arrangement using an electrochemical worksta-
tion CHI 650D, CH Instruments (Austin, USA). The
electrochemical cell consisted of a gold disk electrode sensor as
a working electrode, a platinum wire counter electrode and a
Ag/AgCl (3 M KCl) reference electrode. Electrochemical signals
were measured in 1 PBS buﬀer (pH 7.4) containing 2.5 mM
[Fe(CN)6]
3/[Fe(CN)6]
4 (1 : 1) and 0.1 M KCl. DP signals were
obtained with a potential step of 4 mV, a pulse amplitude of 50
mV, a pulse width of 200 ms, a sampling width of 16.7 ms and a
pulse period of 500 ms. The F-EIS spectra were recorded in 1
PBS buﬀer (pH 7.4) containing 2.5 mM [Fe(CN)6]
3/[Fe(CN)6]
4
(1 : 1) and 0.1 M KCl using an alternating current voltage of 5
mV, with the frequency range of 0.1 (or 1) Hz to 100 kHz. During
the run, the bias DC current was applied below a frequency of
100 Hz. The faradaic current generated by the K3[Fe(CN)6]/
K4[Fe(CN)6] probe accounts for the presence of a biomolecule.
The current changes corresponding to ovalbumin detection
were calculated as follows:
% Decrease of DPV peak current ¼ (Ibefore  Iafter)  100/Ibefore
(1)
where Ibefore ¼ peak current at the ovalbumin capture step [e.g.,
current recorded at biotin-BSA/multivalent streptavidin/bio-
tinylated SNA lectin/designated concentration of ovalbumin
(either in buﬀer or spiked into 1 in 1000 serum)] and Iaer ¼
peak current at the detection step [e.g., current recorded at
biotin-BSA/multivalent streptavidin/biotinylated SNA lectin/
designated concentration of ovalbumin (either in buﬀer or
spiked into 1 in 1000 serum)/1 in 1000 anti-ovalbumin poly-
clonal antibody].
For each electrode, the peak current was normalized with a DPV
response obtained at the initial step when electrodes were clean.
Results and Discussion
Construction of biosensor
Fig. 1 describes an assembly scheme of the biosensor. As
reported previously,18 biotin labeled BSA is used for coating the5972 | Analyst, 2014, 139, 5970–5976gold electrode surface. Subsequently, multivalent streptavidin
was used as a linker to immobilize the biotin labeled SNA lectin
to form a bio-recognition layer on the electrode surface. The
formation of the bio-recognition layer on the electrode surface
aﬀects analytical performance of the biosensor and in our
experiments this formation is controlled by attachment of
biotin-BSA, streptavidin and biotinylated SNA lectin. To achieve
maximal analytical performance, we optimized binding condi-
tions for all three biomolecules one aer another by incubating
electrodes with three diﬀerent concentrations of biotin-BSA,
multivalent streptavidin and biotinylated SNA lectin.
To determine the optimal biotin-BSA concentration at rst,
we incubated thoroughly cleaned gold electrodes with 100 mg
mL1, 500 mg mL1 and 1000 mg mL1 solution of biotin-BSA for
45 min. The electrodes were washed three times with 1 PBS,
followed by F-EIS measurements to determine the optimal
biotin-BSA concentration. As compared to 100 mg mL1, incu-
bation of electrodes with 500 mg mL1 concentration of biotin-
BSA showed an increase in size of the semicircle on the Nyquist
plot (Fig. 2A, i vs. ii) suggesting an increased electron transfer
resistance (Rct). There was no further increase in Rct at 1000 mg
mL1 biotin-BSA concentration as compared to 500 mg mL1This journal is © The Royal Society of Chemistry 2014
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View Article Online(Fig. 2A, ii vs. iii). As 500 mg mL1 biotin-BSA showed best F-EIS
i.e. maximum Rct response, the same binding condition was
used for subsequent experiments. Next, F-EIS for three diﬀerent
concentrations 100 mg mL1, 500 mg mL1 and 1000 mg mL1 of
multivalent streptavidin under optimal biotin-BSA binding
conditions was obtained. As shown in Fig. 2C, incubation of the
electrode with a 500 mg mL1 concentration of multivalent
streptavidin showed a maximum Rct under optimal biotin-BSA
binding conditions. Similarly, as shown in Figure 2E, 500 mg
mL1 of biotinylated SNA lectin showed the best F-EIS response
under optimal biotin-BSA and multivalent streptavidin binding
conditions. To conrm F-EIS results we conducted parallel DPV
measurements and as shown in Fig. 2B, D and F, there was a
decrease in peak DPV current corresponding to an increase in
Rct suggesting reduction in actual electron transfer between the
electrode/redox electrolyte double layer with increased resis-
tance. For all three biomolecules, the maximum Rct and
minimal DPV peak current was observed at 500 mg mL1
concentration. Moreover, there was no further increase in Rct at
a higher concentration i.e. 1000 mg mL1. This suggests that the
electrode surface is getting saturated when incubated with 500
mg mL1 concentration of biomolecules and there is no non-
specic binding of the protein directly on the electrode surface
at a higher concentration. As the protein binding to the elec-
trode surface is showing saturation without any non-specic
binding, it is anticipated that there will be minimal or no non-
specic binding of biomolecule of interest directly to the elec-
trode surface during further stages of the experiment.Fig. 3 (A) Nyquist plots and (B) diﬀerential pulse voltammetric
responses for monitoring (i) biotin-BSA (ii) biotin-BSA/multivalent
streptavidin (iii) biotin-BSA/multivalent streptavidin/SNA lectin (iv)
biotin-BSA/multivalent streptavidin/SNA lectin/1 ng mL1 ovalbumin
and (v) biotin-BSA/multivalent streptavidin/SNA lectin/1 ng mL1
ovalbumin/anti-ovalbumin antibody in 1 PBS buﬀer containing 2.5
mM K3[Fe(CN)6], 2.5 mM K4[Fe(CN)6]$3H2O and 0.1 M KCl. (C) Diﬀer-
ential pulse voltammetric responses to detect any non-speciﬁc
binding of anti-ovalbumin antibody with SNA lectin (i) biotin-BSA/
multivalent streptavidin/SNA lectin and (ii) biotin-BSA/multivalent
streptavidin/SNA lectin/anti-ovalbumin antibody.Glycoprotein capture and detection
Aer optimizing conditions for SNA lectin immobilization on
the electrode surface, next we captured glycoprotein ovalbumin
in 150 mM NaCl solution containing 0.1 mM Ca2+. The forma-
tion of bio-recognition layers and capture of ovalbumin was
followed by electrochemical detection. As shown in Fig. 3A, the
biotin-BSA coated electrode gave rise to the smallest semicircle
(Fig. 3Ai), followed by streptavidin (Fig. 3Aii), SNA lectin
(Fig. 3Aiii) and ovalbumin (Fig. 3Aiv) which showed a gradual
increase in semicircle indicating an increase in electron trans-
fer resistance. In line with changes observed in impedance, we
observed a corresponding decrease in peak DPV current
(Fig. 3B). These results conrm the results shown in a previous
section for successful formation of bio-recognition layers on the
electrode surface. Next, it demonstrates successful capture of
target glycoprotein ovalbumin on a SNA biosensor with elec-
trochemical detection.
Lectins generally recognize glycan structures with low
aﬃnity but with high avidity mainly through hydrogen bonding,
hydrophobic interactions and van der Waals forces.29 In fact,
glycan structure specic interactions of a glycoprotein with
lectins are very well demonstrated in the recent past mainly
using sialic acid binding lectin biosensors.25–27,30 Incubation of
the SNA lectin biosensor with asialofetuin, a non-sialic acid
expressing glycoform variant of glycoprotein fetuin, showed
very minimal change in the baseline impedance.25–27,30 In
contrast, a linear increase from baseline impedance wasThis journal is © The Royal Society of Chemistry 2014 Analyst, 2014, 139, 5970–5976 | 5973
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View Article Onlineobserved when the SNA lectin biosensor was incubated with an
increasing concentration of fetuin expressing a correct glycan
epitope.25–27,30 Apart from showing very high binding specicity
towards the glycan epitope, these SNA lectin biosensors have
demonstrated sensitivity for glycoprotein detection (e.g. fetuin)
up to attomolar concentration.25–27,30 SNA along with other
electrochemical lectin biosensors developed so far has been
applied to glycan proling of healthy and rheumatoid arthritis
human serum samples,27 monitor glycosylation changes
between normal and cancerous pancreatic cell extracts,25
dengue diagnosis31 and microorganism recognition,32 without
detecting specic glycoproteins. Detection of both glycan and
protein epitopes of a glycoprotein is required to provide the
specicity to measure the glycosylation-specic biomarker, for
example fucosylated alpha-fetoprotein. Therefore, following the
capture of ovalbumin glycoprotein using a SNA lectin biosensor,
we interrogated the ovalbumin protein backbone using a poly-
clonal anti-ovalbumin antibody. Upon capturing ovalbumin on
a SNA biosensor, electrodes were incubated with 1 in 1000
dilution of anti-ovalbumin antibody, followed by F-EIS and DPV
measurements. As compared to the ovalbumin capture step
(Fig. 3Aiv) incubation of the electrode with an anti-ovalbumin
antibody (Fig. 3Av) showed an increase in impedance, with a
corresponding decrease in DPV peak current (Fig. 3B). These
results indicate stepwise construction of the bio-recognition
layer, capture of ovalbumin on the SNA biosensor and detection
of ovalbumin using a polyclonal anti-ovalbumin antibody. As F-
EIS and DPV techniques showed an excellent agreement
between the results obtained for stepwise binding of biomole-
cules on the sensor surface, we presented only DPV responses
for remaining all experiments.
As antibodies are glycoproteins themselves, they may directly
interact with lectins which may lead to false positive results.
Therefore, contribution of a false positive response due to direct
interaction between the SNA lectin and a polyclonal anti-oval-
bumin antibody was tested. The gold electrode modied with
biotin-BSA/streptavidin/SNA lectin was directly incubated with
an anti-ovalbumin antibody to allow any possible direct inter-
action between them. As shown in Fig. 3C we did not observe
any change in the DPV response between the biotin-BSA/strep-
tavidin/SNA lectin and the biotin-BSA/streptavidin/SNA lectin
incubated with an anti-ovalbumin antibody. This nding indi-
cates that there was no direct interaction between the oval-
bumin antibody with the SNA lectin.
Thus, we demonstrate stepwise formation of a bio-recogni-
tion layer; capture of glycoprotein ovalbumin on the SNA
biosensor surface followed by detection of ovalbumin using an
anti-ovalbumin antibody and label-free electrochemical detec-
tion using F-EIS and DPV measurements. Moreover, we did not
observe any direct interaction between the lectin and the anti-
body which excludes possibility for false positive results. To the
best of our knowledge, this is the rst electrochemical
biosensor which interrogates both the glycan epitope of a
glycoprotein using a lectin and protein epitope using an anti-
protein antibody with label-free electrochemical monitoring.5974 | Analyst, 2014, 139, 5970–5976Detection of ovalbumin in serum
To evaluate the biosensor performance under more physiolog-
ical conditions, we conducted a series of experiments in which
ovalbumin was spiked into diluted human serum collected
from a healthy donor. To mimic biomarker detection condi-
tions, ovalbumin at a nal concentration of 1 ng mL1 was
spiked into the 1 : 1000 serum sample. Similar dilution of the
serum sample has been recommended to study the overall
changes in glycan proles using electrochemical detection.27
Blood is very heterogeneous in terms of its protein composition,
consisting of proteins with abundance varying by several orders
of magnitude. Top six abundant plasma proteins account for
85% of the total plasma proteome.33 Out of them, ve are found
to be glycosylated (transferrin, haptoglobin, a1-antitrypsin, IgG,
and IgA) and show varying degree of binding to the SNA lectin.
This means that one would expect a signicant amount of
glycoprotein capture when the electrode immobilized with the
SNA lectin is incubated with the serum/plasma sample. As can
be seen in Fig. 4A, the DPV peak current was signicantly
reduced when the SNA lectin modied electrode was incubated
with the serum sample (Fig. 4A, i vs. ii). However, there was no
further decrease in the DPV response with anti-ovalbumin
antibody incubation suggesting that the antibody did not bind
non-specically with any SNA lectin-bound human serum
proteins (Fig. 4A, ii vs. iii).
When ovalbumin was spiked into serum, incubation of the
electrode with the polyclonal anti-ovalbumin antibody
(Fig. 4Bii) showed signicant reduction in the peak DPV
response as compared to the DPV peak current resulted at the
ovalbumin capture step in serum (Fig. 4Bi). These data clearly
demonstrate that our method is highly eﬀective for specic
detection of ovalbumin glycoprotein in the presence of large
excess of several other SNA lectin binding proteins in serum.
To assess the dynamic range and lower limit of detection of
our method, a dilution series of ovalbumin protein (1 pg mL1
to 10 ng mL1) was spiked in diluted serum. For each oval-
bumin concentration, the electrochemical response was
measured at the glycoprotein capture step and detection step
using an anti-ovalbumin antibody. The percentage change in
the peak current between these two measurements is attributed
to the amount of ovalbumin present in the sample. As shown in
Fig. 4C, there was a gradual increase in the percentage
change in DPV peak current with increasing concentrations
of ovalbumin spiked in serum ranging from 10 pg mL1 to
500 pg mL1.
Beyond 500 pg mL1, there was no further increase in DPV
response suggesting saturation of the glycoprotein capture on
the electrode surface. The lower limit of detection of 10 pg mL1
described here is comparable with previous electrochemical
glycan proling studies.25,27 This 10 pg mL1 lower limit of
detection in a 1000 fold diluted serum sample will actually
translate into 10 ng mL1 in the actual undiluted sample.
Previously published lectin electrochemical biosensors showed
femtomolar sensitivity and outperformed conventional lectin-
ELISA and lectin-microarrays by several fold in terms of lower
limit of detection.25,27 Unlike previous studies which onlyThis journal is © The Royal Society of Chemistry 2014
Fig. 4 Diﬀerential pulse voltammetric responses for (A) detection of
SNA binding proteins present in human serum (i) biotin-BSA/multiva-
lent streptavidin/SNA lectin (ii) capturing SNA lectin binding glyco-
proteins present in human serum (1 in 1000 dilution) and (iii) detection
of any non-speciﬁc recognition of SNA bound serum glycoprotein
using an anti-ovalbumin antibody. (B) Detection of ovalbumin spiked in
human serum (i) capturing 1 ng mL1 ovalbumin in human serum (1 in
1000 dilution) using SNA lectin and (ii) its detection using an anti-
ovalbumin antibody. (C) Calibration plot for % change in the diﬀerential
pulse voltammetric response for detection of a designated concen-
tration of ovalbumin spiked in human serum (1 in 1000 dilution) using
an anti-ovalbumin antibody. Each data point represents average  SD
(standard deviation) of 3 independent experiments.
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View Article Onlineinterrogated glycan, here we interrogated both glycan and
protein epitopes of a glycoprotein in the background of diluted
serum with a detection limit of 10 pg mL1. The detection limit
of our assay could be further improved via incorporation and
optimization of the device geometry and experimental param-
eters.34 Moreover, designing a multiplexed electrochemical
biosensor25,34 would help to monitor the panel of clinically
relevant glycoprotein biomarkers in parallel.This journal is © The Royal Society of Chemistry 2014Conclusions
In this proof-of-concept study we demonstrated interrogation of
glycan along with a protein epitope of a glycoprotein ovalbumin
using SNA lectin and an anti-ovalbumin antibody respectively
followed by label-free electrochemical detection in the back-
ground of diluted serum. Our lectin-antibody biosensor detects
specic glycans and the glycoprotein to which the glycan is
attached, hence provides increased specicity over existing
lectin biosensors. Furthermore, with a detection limit of 10 pg
mL1, the lectin-antibody electrochemical biosensor described
here could be developed further to achieve point-of-care diag-
nosis for clinically relevant glycoprotein biomarkers.Conﬂict of interest
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